Q2 EPS Estimates for Kodiak Sciences Boosted by Analyst

Kodiak Sciences Inc. (NASDAQ:KOD) – Analysts at HC Wainwright raised their Q2 2026 earnings per share (EPS) estimates for shares of Kodiak Sciences in a research note issued to investors on Monday, May 11th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings of ($0.95) per share for the quarter, up from their prior forecast of ($0.96). HC Wainwright has a “Buy” rating and a $58.00 price target on the stock. The consensus estimate for Kodiak Sciences’ current full-year earnings is ($4.04) per share. HC Wainwright also issued estimates for Kodiak Sciences’ Q3 2026 earnings at ($0.80) EPS, Q4 2026 earnings at ($0.81) EPS, FY2026 earnings at ($3.48) EPS, FY2027 earnings at ($2.92) EPS, FY2028 earnings at ($1.74) EPS, FY2029 earnings at $0.39 EPS and FY2030 earnings at $3.20 EPS.

Several other analysts also recently weighed in on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Kodiak Sciences in a research report on Thursday, January 22nd. UBS Group lifted their price target on Kodiak Sciences from $50.00 to $80.00 and gave the company a “buy” rating in a report on Friday, March 27th. Finally, Chardan Capital raised Kodiak Sciences from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $14.00 to $61.00 in a report on Monday. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $42.14.

Kodiak Sciences Stock Performance

Shares of KOD opened at $39.49 on Wednesday. The firm has a fifty day moving average of $35.72 and a 200-day moving average of $28.07. The company has a market cap of $2.47 billion, a price-to-earnings ratio of -9.47 and a beta of 2.32. Kodiak Sciences has a 1 year low of $2.81 and a 1 year high of $47.84.

Kodiak Sciences (NASDAQ:KOD) last issued its earnings results on Thursday, May 7th. The company reported ($0.94) earnings per share for the quarter, missing the consensus estimate of ($0.93) by ($0.01).

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in KOD. Westfuller Advisors LLC acquired a new position in shares of Kodiak Sciences during the first quarter valued at approximately $26,000. V Square Quantitative Management LLC acquired a new stake in Kodiak Sciences in the first quarter worth approximately $26,000. EverSource Wealth Advisors LLC boosted its stake in Kodiak Sciences by 1,221.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company’s stock valued at $28,000 after purchasing an additional 916 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in Kodiak Sciences during the 4th quarter valued at $29,000. Finally, Headlands Technologies LLC increased its position in shares of Kodiak Sciences by 256.4% during the 2nd quarter. Headlands Technologies LLC now owns 8,083 shares of the company’s stock valued at $30,000 after purchasing an additional 5,815 shares during the period. 89.06% of the stock is currently owned by institutional investors.

About Kodiak Sciences

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.